SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcashs sharp pullback after a steep rally is dominating discussion, with traders split between viewing it as a buyable consolidation and warning of an overheated pump-and-dump or deeper correction. Bulls point to renewed interest in privacy-focused crypto and ETF and institutional attention, while others cite Bitcoin weakness and profit-taking.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiak surged after its Phase 3 DAYBREAK trial found that Zenkuda and KSI-501 met key endpoints in wet AMD, with Zenkuda showing potential for longer intervals between treatments and a planned FDA filing. Traders celebrated the results and a possible short squeeze, while others questioned the drugs edge over newer competitors and warned that Kodiaks precommercial status could mean financing needs and sharp volatility.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs weak Q2 results and softer-than-expected Q3 outlook are fueling concern about losses, vehicle margins and demand amid intense Chinese EV competition, extending a prolonged selloff that traders also associate with broader weakness in Chinese stocks. Some investors point to the robotics units outside funding and growth potential as a counterweight, while skeptics question whether that can offset the companys profitability and execution risks.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants reported selection by The Clearing House for its on-chain money initiative is driving attention, with traders linking the banking-infrastructure news to a sharp rally in QNT. The community is divided between dip-buyers citing limited token supply and skeptics questioning whether the deal creates meaningful demand for QNT itself; a steep pullback has intensified profit-taking and volatility.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Elevated Treasury yields and oil- and Iran-related uncertainty are weighing on the broad market, with traders also pointing to weak breadth and concerns about AI-heavy stocks. The conversation is split between calls for further downside and dip-buying or bounce expectations.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

CLF is drawing attention after a sharp decline as traders react to a proposed Iowa steel complex linked to Mesabi Metallics, worrying that added capacity could threaten Cliffs over time. Many question whether the project will be financed or completed and say it is years away, while others point to Hamilton production cuts and layoffs as a more immediate concern and view the selloff as overdone.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Vikings large stock-and-convertible-note offering, announced after encouraging VK2735 obesity-maintenance data, is driving the discussion and weighing on shares as investors digest dilution. Traders are divided between criticism of the offerings timing and managements execution, and the view that the added capital supports Phase 3 development; buyout and partnership talk remains speculative.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFAs move to let Fannie Mae and Freddie Mac lenders use VantageScore alongside FICO is raising concerns that competition could erode FICOs long-standing mortgage-scoring advantage and pricing power, driving a sharp repricing of the shares. Traders debate whether the threat is overstated given FICOs established business or signals a lasting loss of its moat, while some see the selloff as a buying opportunity.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas strategic equity investment and clinical-trial collaboration with Summit have drawn attention, with traders viewing the deal as added financing and pharmaceutical-industry validation for ivonescimab. The community is broadly upbeat, though some caution that the agreement is an investment and collaborationnot an acquisitionand does not remove the FDA and clinical-trial risks.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDBs CEO CJ Desai stepped down to join Meta, with former CEO Dev Ittycheria returning as interim chief while the board searches for a successor. Traders are split between viewing the abrupt exit ahead of investor day as a source of leadership uncertainty behind the sharp selloff and calling it an overreaction, citing reaffirmed guidance and Ittycherias return as signs of continuity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PAPR is currently trading near its 52 week high, which is a good sign. https://www.chartmill.com/stock/quote/PAPR/technical-analysis?key=ee70d1da-4e3b-46fb-8e9a-7de821753cd7&amp;utm_source=stocktwits&amp;utm_medium=TA&amp;utm_content=PAPR&amp;utm_campaign=social_tracking

Technical Analysis of INNOVATOR U.S. EQUITY POWER(NYSEARCA:PAPR) stock. Technical Analyis of trend, support and resistance, indicators, patterns and signals.